EDSA - Edesa slated for a panel discussion at a government COVID-19 event

Par Nijhawan, CEO of Edesa Biotech ([[EDSA]] +15.5%) is scheduled to join a panel discussion on COVID-19 organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate.In the virtual event, Dr. Nijhawan will highlight the importance of developing multiple countermeasures to the COVID-19 pandemic, including therapies, like Edesa's EB05 drug candidate, a statement from the company said.A monoclonal antibody therapy, EB05 is undergoing development as a treatment for Acute Respiratory Distress Syndrome (“ARDS”) in COVID-19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID-19 patients.In October, Edesa announced the FDA signoff for a Phase 2/3 clinical trial evaluating EB05 in hospitalized COVID-19 patients with or are at risk of developing ARDS.

For further details see:

Edesa slated for a panel discussion at a government COVID-19 event